Literature DB >> 7553995

Mivacurium infusion requirements following vecuronium: different response between adults and children.

W Denman1, N Goudsouzian.   

Abstract

The mivacurium infusion requirements following vecuronium were evaluated in 15 adults and 15 children in an open prospective clinical study. This study was undertaken to elucidate whether potentiation of effect occurred when a mivacurium infusion was administered after vecuronium was used for the facilitation of tracheal intubation. The adult patients were anaesthetized with N2O:02, propofol and fentanyl, the children with halothane (1%) N2O:O2. Vecuronium 100 micrograms.kg-1 was administered during stimulation of the ulnar nerve with train-of-four stimuli at 0.1 Hz. The force of contraction of adductor pollicis was recorded. Upon recovery of the twitch response from vecuronium, a mivacurium infusion was started at 4 micrograms.kg-1.min-1, thereafter adjustments were made to maintain the first twitch of the train-of-four (T1) at 1-10% of control. The mean (+/- SE) initial infusion requirements in children of mivacurium was 4.3 (0.4) micrograms.kg-1.min-1 which increased linearly (P < 0.001) over the next 90 min to 10 micrograms.kg-1.min-1. In adults the infusion requirement was lower than in children and remained at approximately 3 micrograms.kg-1.min-1 over the next 75 min. At the end of the surgical procedure, the children recovered faster than the adults with no child requiring reversal. Because of prolonged recovery ( > 20 min), seven adults required reversal with 15-70 micrograms.kg-1 neostigmine. Mivacurium infusion requirements following vecuronium are higher in children than adults. Potentiation of the effects of mivacurium were seen when vecuronium preceded mivacurium. This potentiation of effect lasted longer in adults than in children.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7553995     DOI: 10.1007/BF03011876

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  31 in total

Review 1.  Release of transmitter at the neuromuscular junction.

Authors:  F G Standaert
Journal:  Br J Anaesth       Date:  1982-02       Impact factor: 9.166

2.  Recovery from pancuronium and vecuronium administered simultaneously in the isolated forearm and the effect on recovery following administration after cross-over of drugs.

Authors:  S A Feldman; N J Fauvel; J R Hood
Journal:  Anesth Analg       Date:  1993-01       Impact factor: 5.108

3.  Potentiation and antagonism of vecuronium by decamethonium.

Authors:  S Feldman; N Fauvel
Journal:  Anesth Analg       Date:  1993-03       Impact factor: 5.108

Review 4.  Prejunctional and postjunctional cholinoceptors at the neuromuscular junction.

Authors:  W C Bowman
Journal:  Anesth Analg       Date:  1980-12       Impact factor: 5.108

Review 5.  Acetylcholine receptor: an allosteric protein.

Authors:  J P Changeux; A Devillers-Thiéry; P Chemouilli
Journal:  Science       Date:  1984-09-21       Impact factor: 47.728

6.  Interaction between pancuronium bromide and vecuronium bromide.

Authors:  O M Rashkovsky; S Agoston; J M Ket
Journal:  Br J Anaesth       Date:  1985-11       Impact factor: 9.166

7.  Vecuronium and d-tubocurarine combination: potentiation of effect.

Authors:  R K Mirakhur; F M Gibson; C J Ferres
Journal:  Anesth Analg       Date:  1985-07       Impact factor: 5.108

8.  Synergism between atracurium and mivacurium compared with that between vecuronium and mivacurium.

Authors:  L Jalkanen; O A Meretoja; T Taivainen; B W Brandom; B Dayal
Journal:  Anesth Analg       Date:  1994-11       Impact factor: 5.108

9.  Age-dependence of the dose-response curve of vecuronium in pediatric patients during balanced anesthesia.

Authors:  O A Meretoja; K Wirtavuori; P J Neuvonen
Journal:  Anesth Analg       Date:  1988-01       Impact factor: 5.108

10.  Equilibrium binding of [3H]tubocurarine and [3H]acetylcholine by Torpedo postsynaptic membranes: stoichiometry and ligand interactions.

Authors:  R R Neubig; J B Cohen
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.